Our research focuses on making personalized oncology treatment a reality. Our goal is to design tests that will enable clinicians to predict which patients will have a good probability of benefiting from a therapeutic agent. These tests enable us to characterize individual tumors at the molecular level. The promise of effective predictors of response to anti-cancer agents is that they will guide clinicians in the selection of the best medicine for each patient, which in turn, is expected to improve prognosis and lengthen survival. We are currently engaged in three projects, two in lung cancer and one in glioma. These projects are funded by grants from the Maine Cancer Foundation and from the Schering-Plough Corporation.